Table 1.

C. elegans P450 genes with reported human orthologues, phenotypes, substrates, inhibitors, and/or expression patterns

C. elegans gene	Human orthologue	Knockdown phenotype	Substrates	Inducers (mRNA expression)	Tissue Expression	Reference
daf-9	CYP2S1	Abnormal dauer formation	3-keto-sterols		nervous system, intestine, spermatheca, vulval muscle	(Gill et al. 2004; Mak and Ruvkun 2004; Motola et al. 2006)
cyp-13A1	CYP3A4/TBXAS1	None reported			coelomocyte, gonad
cyp-13A4	CYP3A4/5/43	Growth delay, Uncoordinated movement			broad somatic expression	(Simmer et al. 2003a; Kamath et al. 2003)
cyp-13A7	CYP3A4/TBXAS1	None reported		tetrabromobisphenol A, rifampcin	intestine	(Liu et al. 2020; Chakrapani et al 2008)
cyp-13A8	CYP3A7/51P	Clear body cavity, Sluggish, some Embryonic lethality				(Kamath et al. 2003)
cyp-13A10	CYP3A4/7/43	None reported		tetrabromobisphenol A	neuron, germline, embryos	(Liu et al. 2020)
cyp-13A12	CYP3A4/5/7	None reported		tetrabromobisphenol A, acrylamide	marginal cells	(Liu et al. 2020; Hasegawa et al. 2007)
cyp-14A5	CYP2U1	Short defecation cycle	PCB52		GABAergic neuron, somatic gonad precursor, intestine	(Schafer et al. 2009)
cyp-29A3	CYP4V2	Short defecation cycle	eicosapentaenoic acid	1-methylnicotinamide, chlorpyrifos, 4-bromodiphenyl ether	neurons, intestine, body wall muscle, hypodermis, coelomocytes	(Kulas et al. 2008; Schmeisser et al. 2013; Viñuela et al. 2010)
cyp-31A1 (pseudogene)	N/A	Embryonic lethality				(Simmer et al. 2003b)
cyp-31A2	CYP4V2	Embryonic lethality			hypodermis, germline, neurons	(Simmer et al. 2003a)
cyp-31A5	CYP4V2	Embryonic lethality			germline, AFD neurons	(Simmer et al. 2003a)
cyp-33E2	CYP2J2	Reduced pharyngeal pumping, Extended lifespan, Reduced brood size	Long chain fatty acids, eicosapentaenoic acid		pharynx, intestine, neurons	(Deline et al. 2015; Kulas et al. 2008)
cyp-34A9			tolbutamide			(Harlow et al. 2018)
cyp-35A1	CYP2C18 CYP2D7 CYP2E1	Drug resistant1		3-bromopyruvate, β-naphthoflavone, PCB52, lansoprazole, primaquine	intestine	(Gu et al. 2020; Menzel et al 2001)
cyp-35A2	CYP2C18 CYP2D7 CYP2E1	Drug resistant1		3-bromopyruvate, β-naphthoflavone, PCB52, lansoprazole, atrazine	intestine, neurons (PVD/OLL)	(Gu et al. 2020; Menzel et al 2001; Chakrapani et al 2008)
cyp-35A3	CYP2C18 CYP2D7 CYP2E1	Reduced fat storage		chlorpyrifos, β-naphthoflavone, PCB52, lansoprazole, primaquine	intestine, AFD neurons	(Ashrafi et al. 2003; Viñuela et al. 2010; Menzel et al 2001)
cyp-35A4	CYP2C18 CYP2D7 CYP2E1	Short defecation cycle, Chemical response variant		3-bromopyruvate, β-naphthoflavone, PCB52, lansoprazole, primaquine	muscle, intestine, neurons	(Gu et al. 2020; Menzel et al 2001)
cyp-35A5	CYP2C18 CYP2D7	Reduced fat storage		3-bromopyruvate (weak), β-naphthoflavone, PCB52, lansoprazole, primaquine, atrazine	intestine	(Ashrafi et al. 2003; Gu et al. 2020; Kulas et al. 2008; Menzel et al 2001)
cyp-35B1	CYP2C18 CYP2D7 CYP2E1	Reduced fat storage		β-naphthoflavone, ethanol	intestine, hypodermis, dopaminergic neurons	(Ashrafi et al. 2003; Menzel et al 2001)
cyp-35B2				β-naphthoflavone, lansoprazole, primaquine, ethanol		(Menzel et al 2001)
cyp-35C1	CYP2C18 CYP2D7 CYP2E1	Drug resistant1, Oxidative stress resistant		3-bromopyruvate, tetrabromobisphenol A, fluoranthene, β-naphthoflavone, PCB52, lansoprazole, primaquine	intestine, neurons (AFD/OLL/PVD)	(Gu et al. 2020; Liu et al. 2020; Menzel et al 2001; Taubert et al. 2008)
cyp-42A1	CYP4V2	Uncoordinated movement			hypodermis, intestine	(Kamath et al. 2003)

¹Term “Drug resistant” indicates reducing defects produced by a particular drug treatment (e.g. reproduction decline after exposure to xenobiotics)